Correction: The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment

Correction: The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment

Bibliographic Details
Main Authors:	Bisheng Cheng, Lingfeng Li, Yongxin Wu, Tianlong Luo, Chen Tang, Qiong Wang, Qianghua Zhou, Jilin Wu, Yiming Lai, Dingjun Zhu, Tao Du, Hai Huang
Format:	Article
Language:	English
Published:	BMC 2024-02-01
Series:	Cell & Bioscience
Online Access:	https://doi.org/10.1186/s13578-023-01178-1

Similar Items

The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment
by: Bisheng Cheng, et al.
Published: (2023-11-01)

Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway
by: Bisheng Cheng, et al.
Published: (2024-03-01)

Correction: Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway
by: Bisheng Cheng, et al.
Published: (2024-12-01)

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
by: Ioannis Boukovinas, et al.
Published: (2008-01-01)

Recent Developments in Small-Molecule Fluorescent Probes for Cellular Senescence
by: Junyoung Park, et al.
Published: (2024-07-01)

Undifferentiated prostate cancer treated with docetaxel
by: Masaki Kobayashi, et al.
Published: (2020-07-01)

Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel
by: Mingyue Xia, et al.
Published: (2022-11-01)

Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells <it>in vitro </it>and <it>in vivo</it>: implication of RRM2 in angiogenesis
by: Zhou Bingsen, et al.
Published: (2009-02-01)

Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer
by: Julia Kallenbach, et al.
Published: (2022-12-01)

Corrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel
by: Mingyue Xia, et al.
Published: (2023-07-01)

Role of hypoxia in cellular senescence
by: Haoyu Gao, et al.
Published: (2023-08-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Computer-aided analysis of quercetin mechanism of overcoming docetaxel resistance in docetaxel-resistant prostate cancer
by: Victor Omoboyede, et al.
Published: (2023-04-01)

Integrative analysis of cuproptosis-related lncRNAs: Unveiling prognostic significance, immune microenvironment, and copper-induced mechanisms in prostate cancer
by: Haitao Zhong, et al.
Published: (2025-01-01)

Increased ABCC4 Expression Induced by ERRα Leads to Docetaxel Resistance via Efflux of Docetaxel in Prostate Cancer
by: Houbao Huang, et al.
Published: (2020-08-01)

Os genes ERCC1 e RRM1 no carcinoma broncopulmonar ERCC1 and RRM1 genes in lung cancer
by: Lina Carvalho, et al.
Published: (2009-08-01)

Evidence for a Hepatitis B Virus Short RNA Fragment Directly Targeting the Cellular RRM2 Gene
by: Karin Broennimann, et al.
Published: (2022-07-01)

Cellular senescence: A potential mode of circular RNAs regulating prostate cancer
by: Yunpeng Li, et al.
Published: (2023-12-01)

Small molecule modulation of splicing factor expression is associated with rescue from cellular senescence
by: Latorre, E, et al.
Published: (2017)

Unravelling Cellular Mechanisms of Stem Cell Senescence: An Aid from Natural Bioactive Molecules
by: Sara Cruciani, et al.
Published: (2020-03-01)

Small molecule modulation of splicing factor expression is associated with rescue from cellular senescence
by: Eva Latorre, et al.
Published: (2017-10-01)

Epithelial-Mesenchymal Transition in Docetaxel-Resistant Prostate Cancer
by: Camila Libardi do Amaral
Published: (2017-06-01)

Cellular Senescence in Health, Disease, and Lens Aging
by: Ying Qin, et al.
Published: (2025-02-01)

Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells
by: Xiao Wang, et al.
Published: (2022-12-01)

p53 deficiency mediates cisplatin resistance by upregulating RRM2 and crotonylation of RRM2K283 through the downregulation of SIRT7
by: Liangjie Sun, et al.
Published: (2024-06-01)

Cellular senescence in asthma: from pathogenesis to therapeutic challenges
by: Rongjun Wan, et al.
Published: (2023-08-01)

Weekly-docetaxel chemotherapy for Taiwanese patients withmetastatic castrate-resistant prostate cancer
by: Cheng-Li Kao, et al.
Published: (2015-06-01)

HBx promotes tumorigenicity through RRM2-mediated autophagy in hepatocellular carcinoma
by: Yaqun Li, et al.
Published: (2024-09-01)

Higher expression of acetyl-tubulin may induce docetaxel resistance in prostate cancer cells
by: Yu-Hua Lin, et al.
Published: (2015-06-01)

IGF2BP3 regulates the expression of RRM2 and promotes the progression of rheumatoid arthritis via RRM2/Akt/MMP-9 pathway.
by: Zhaonan Ban, et al.
Published: (2024-01-01)

p52 signaling promotes cellular senescence
by: Giovanna M. Bernal, et al.
Published: (2022-04-01)

The chemomodulatory effects of glufosfamide on docetaxel cytotoxicity in prostate cancer cells
by: Reem T. Attia, et al.
Published: (2016-06-01)

Radioenhancement with the Combination of Docetaxel and Ultrasound Microbubbles: In Vivo Prostate Cancer
by: Firas Almasri, et al.
Published: (2023-05-01)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
by: Prestwich Robin, et al.
Published: (2011-06-01)

Hemorrhagic Cystitis in a Patient Receiving Docetaxel for Prostate Cancer
by: A.I. Ntekim, et al.
Published: (2010-01-01)

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
by: Rani Sweta, et al.
Published: (2011-10-01)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
by: Victoria J Sinibaldi
Published: (2008-01-01)

Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer
by: Ke Li, et al.
Published: (2019-12-01)

Overcoming docetaxel resistance in prostate cancer: a perspective review
by: Clara Hwang MD
Published: (2012-11-01)

RRM2B Is Frequently Amplified Across Multiple Tumor Types: Implications for DNA Repair, Cellular Survival, and Cancer Therapy
by: Waleed Iqbal, et al.
Published: (2021-03-01)